Ofatumumab plus Fresh Frozen Plasma bei systemischem Lupus erythematodes mit ausgeprägter Hypokomplementämie

• Literatur

• 1 Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 2015; 11 (06) 329-341.
• 2 Ambrose N, Morgan TA, Galloway J. et al. Differences in disease phenotype and severity in SLE across age groups. Lupus 2016; 25 (14) 1542-1550.
• 3 Petri M, Orbai A-M, Alarcón GS. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64 (08) 2677-2686.
• 4 bESID – European Society for Immunodeficiencies [Internet]. [cited 2017 Jun 4]. Available from: https://esid.org/Working-Parties/Registry/Diagnosis-criteria.
• 5 Anolik JH, Barnard J, Owen T. et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56 (09) 3044-3056.
• 6 Anolik JH, Barnard J, Cappione A. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50 (11) 3580-3590.
• 7 Vital EM, Dass S, Buch MH. et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011; 63 (10) 3038-3047.
• 8 Zhu L, Yin Z, Ju B. et al. Altered frequencies of memory B cells in new-onset systemic lupus erythematosus patients. Clin Rheumatol. 2017 Oct 25.
• 9 Furst DE. Serum immunoglobulins and risk of infection: how low can you go?. Semin Arthritis Rheum 2009; 39 (01) 18-29.
• 10 Nazir HF, Elshinawy M, AlRawas A. et al. Efficacy and Safety of Dapsone Versus Trimethoprim/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia. J Pediatr Hematol Oncol 2017; 39 (03) 203-208.
• 11 Arad U, Tzadok S, Amir S. et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011; 29 (08) 1643-1648.
• 12 Mahmoud I, Jellouli M, Boukhris I. et al. Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. J Pediatr. 2017 Jun 8.
• 13 Watson L, Beresford MW, Maynes C. et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus 2015; 24 (01) 10-17.
• 14 El-Hallak M, Binstadt BA, Leichtner AM. et al. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 2007; 150 (04) 376-382.
• 15 Olfat M, Silverman ED, Levy DM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus 2015; 24 (09) 966-972.
• 16 Hogan J, Godron A, Baudouin V. et al. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol Berl Ger. 2017 Aug 5.
• 17 Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol Berl Ger 2017; 32 (06) 1013-1021.
• 18 Ale’ed A, Alsonbul A, Al-Mayouf SM. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int 2014; 34 (04) 529-533.
• 19 Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther 2013; 15 (Suppl. 01) S3.
• 20 Lin TS. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmacogenomics Pers Med 2010; 03: 51-59.
• 21 Wierda WG, Kipps TJ, Mayer J. et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 2010; 28 (10) 1749-1755.
• 22 Md Yusof MY, Shaw D, El-Sherbiny YM. et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis 2017; 76 (11) 1829-1836.
• 23 Haarhaus ML, Svenungsson E, Gunnarsson I. Ofatumumab treatment in lupus nephritis patients. Clin Kidney J 2016; 09 (04) 552-555.
• 24 Taylor PC, Quattrocchi E, Mallett S. et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2011; 70 (12) 2119-2125.
• 25 Wang C-S, Liverman RS, Garro R. et al. Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol Berl Ger 2017; 32 (05) 835-841.
• 26 Vivarelli M, Colucci M, Bonanni A. et al. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. Pediatr Nephrol Berl Ger 2017; 32 (01) 181-184.
• 27 Middleton O, Cosimo E, Dobbin E. et al. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia 2015; 29 (01) 107-114.
• 28 Klepfish A, Schattner A, Ghoti H, Rachmilewitz EA. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol 2007; 08 (04) 361-362.
• 29 Fassbinder T, Saunders U, Mickholz E. et al. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthritis Res Ther 2015; 17: 92.
• 30 Speth F, Wellinghausen N, Haas J-P. [Medicinal prophylaxis during intensified immunosuppression in children and adolescents: part 2]. Z Rheumatol 2013; 72 (09) 896-909.
• 31 Wang N, Shen N, Vyse TJ. et al. Selective IgA deficiency in autoimmune diseases. Mol Med Camb Mass 2011; 17 (11–12): 1383-1396.
• 32 Kaplan B, Kopyltsova Y, Khokhar A. et al. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract 2014; 02 (05) 594-600.
• 33 Reddy V, Klein C, Isenberg DA et al.. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatol Oxf Engl 2017; 56 (07) 1227-1237.
• 34 Speth F, Hinze C, Haas J-P. SAT0503 A Prospective Single-Centre Study on Indicators of Infectious Risk After Rituximab Therapy in Children and Adolescents with Rheumatic Diseases. Ann Rheum Dis 2015; 74 (Suppl. 02) 842.
• 35 Makatsori M, Kiani-Alikhan S, Manson A. et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM Mon J Assoc Physicians 2014; 107 (10) 821-828.